🟡 Regulatory Alert
Medline Industries has issued a correction for convenience kits containing recalled anesthetic components, according to the U.S. Food and Drug Administration (FDA). The company is removing affected Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection products from affected convenience kits as part of a corrective action to ensure patient safety and product integrity.
Key takeaways
- Medline is correcting convenience kits by removing recalled anesthetic injection components manufactured by Huons
- The recalled products contain Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection formulations
- Healthcare facilities using affected convenience kits should consult FDA guidance and verify inventory against recall lists
Corrective action underway across product lines
According to the FDA’s medical device safety alert, Medline is actively removing the affected anesthetic components from convenience kits currently in distribution. Convenience kits—pre-assembled packages containing multiple medical supplies for specific procedures—are widely used in operating rooms and procedural settings to streamline preparation and reduce setup time.
The recall stems from quality and safety concerns related to the Huons-manufactured anesthetic injectables, which are used for local and regional anesthesia during minor and major surgical procedures. This action represents a preventive measure to protect patient safety and ensure that healthcare facilities receive only verified, safe components within their convenience kits.
What healthcare facilities should do now
According to the FDA’s medical device recall tracking system, healthcare facilities should check their current inventory of Medline convenience kits against the specific product lot numbers and serial ranges identified in the correction notice. Any affected kits should be segregated from clinical use until replacement components or corrected kits are received.
Procurement and materials management teams should document which convenience kits have been affected and removed from service, and work with Medline to arrange replacement stock or corrected product shipments. Facilities may also wish to review their vendor agreements to clarify timelines for resolution and any associated costs or replacement terms.
Implications for clinical practice
Operating room and procedural staff should be made aware of the convenience kit correction to prevent inadvertent use of affected kits. For healthcare professionals in pharmacy and prescribing roles, this highlights the importance of systematic verification of anesthetic component sourcing and storage protocols. The correction underscores the value of pre-procedure verification checklists and real-time confirmation that all medications and injectables meet current safety standards before administration.
Medline is correcting affected convenience kits by removing recalled Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection components from distribution.
— U.S. Food and Drug Administration, Medical Device Recalls and Early Alerts
What this means
Frequently asked questions
Which anesthetic products are affected by this convenience kit correction?
The correction affects convenience kits containing Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection formulations manufactured by Huons and distributed by Medline. Specific lot numbers and serial ranges are listed on the FDA alert page.
What should I do if my facility has already used one of the affected convenience kits?
Contact Medline customer service and the FDA’s safety alerts system to report any adverse events or product quality concerns. Consult your institutional pharmacy and risk management teams to document the use and assess any potential patient impact.
How can I verify whether my convenience kit inventory is affected?
Check the specific lot numbers and serial ranges provided in the FDA correction notice and cross-reference with your facility’s receiving records and current stock. Medline customer service can also assist in identifying affected products.
Medline’s proactive correction reflects the evolving expectations for transparency and rapid response in medical device supply chain management. Facilities should use this as an opportunity to review their procedures for verifying component sourcing and implementing real-time checks before clinical use. This action, coordinated with the FDA, demonstrates the importance of ongoing post-market surveillance in protecting patient safety across the healthcare system. For more information on pharmacy safety and prescribing alerts, healthcare professionals can consult GMJ News and institutional safety bulletins.
Source: Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons’s Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection, U.S. Food and Drug Administration
Was this article helpful?
Related Coverage
